This article was originally published in SRA
US FDA to hold public meeting
You may also be interested in...
The rare disease-focused firm will pay $90m up front to acquire Orphan Technologies and its Phase I/II enzyme replacement therapy for homocystinuria. Earnouts up to $427m are possible as well.
Investors in surgical robotics company Auris say Johnson & Johnson failed to support the company per their merger agreement.